信号和转录动态是早期适应致癌性BRAF抑制的基础
bioRxiv : the preprint server for biology
|July 29, 2024
概括
药物诱导的适应导致对抗癌激酶抑制剂的耐药性. 准SRC家族激酶 (SFK) 信号,以补偿BRAF抑制,为黑色素瘤提供了一个潜在的治疗策略.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 药物诱导的细胞适应,包括信号传递和基因调控网络重塑,导致耐药性表型和对抗癌激酶抑制剂的敏感性降低.
- 了解酶抑制后亚细胞事件的时间动态对于克服适应性疗法耐药性至关重要.
研究的目的:
- 解决瘤激酶抑制后和细胞循环重新进入前亚细胞事件的规模和动力学.
- 为了研究在BRAF突变黑色素瘤中响应BRAF激酶抑制剂治疗的适应性信号网络重塑.
- 识别潜在的治疗策略,以克服适应性抵抗.
主要方法:
- 利用基于质谱的蛋白质组学和RNA测序来捕捉BRAF激酶抑制剂暴露后的早期时间点 (分钟,小时,天) 的分子快照.
- 丰富了特定的基因,以监测与生长和生存相关的蛋白质酸化事件的动态.
- 运用动态定义的信号和转录模块的统计推断.
主要成果:
- 观察到BRAF-ERK信号轴的早期和持续抑制以及细胞周期信号的逐渐下调.
- 确定了三种截然不同的,可逆的阶段过渡到静止.
- 揭示了SRC家族激酶 (SFK) 信号传导的支配性补偿诱导,部分是由由于减弱的氧化还原平衡而导致的活性氧物种积累所驱动的.
结论:
- 信号和转录网络的早期时间动态揭示了黑色素瘤的适应性抵抗机制.
- 补偿性SFK信号传递是对BRAF抑制的一个关键适应性反应.
- 与SFK抑制剂的同时治疗表明,在黑色素瘤模型中克服适应性抵抗的翻译潜力.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
MAPK Signaling Cascades
5.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K


